UPDATE 1-Merck's Keytruda fails late-stage study in liver cancer patients
February 19, 2019 at 17:07 PM EST
Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main goals of slowing disease progression and extending the life of patients with a common type of liver cancer, the company said on Tuesday.
